Estrella Immunopharma Appoints Hong Zhang As Chairperson And Board Member Following Dosing Of First Patient In Phase I/II Clinical Trial For EB103 T-Cell Therapy
Estrella Immunopharma Appoints Hong Zhang As Chairperson And Board Member Following Dosing Of First Patient In Phase I/II Clinical Trial For EB103 T-Cell Therapy
Estrella免疫藥物公司在對EB103進行第I / II期臨床試驗的第一個患者進行劑量後，任命張虹爲主席和董事會成員。這是肉瘤細胞治療技術。
Board Expands From Five To Six Directors, CEO Dr. Cheng Liu Continues As Director
董事會從五名擴大到六名董事，首席執行官劉成繼續擔任董事。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。